Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
Jiang Chen, Renan Jin, Jie Zhao, et al.
Cancer Letters (2015) Vol. 367, Iss. 1, pp. 1-11
Closed Access | Times Cited: 232

Showing 1-25 of 232 citing articles:

Dietary Natural Products for Prevention and Treatment of Liver Cancer
Yue Zhou, Ya Li, Tong Zhou, et al.
Nutrients (2016) Vol. 8, Iss. 3, pp. 156-156
Open Access | Times Cited: 375
New advances in the diagnosis and management of hepatocellular carcinoma
Ju Dong Yang, Julie K. Heimbach
BMJ (2020), pp. m3544-m3544
Open Access | Times Cited: 336
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
Junjie Xu, Lin Ji, Yuelong Liang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 335
Molecular therapies for HCC: Looking outside the box
Sandrine Faivre, Lorenza Rimassa, Richard S. Finn
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 342-352
Open Access | Times Cited: 300
Sorafenib: A Review in Hepatocellular Carcinoma
Gillian M. Keating
Targeted Oncology (2017) Vol. 12, Iss. 2, pp. 243-253
Closed Access | Times Cited: 274
Targeting non-coding RNAs to overcome cancer therapy resistance
Baoqing Chen, Mihnea P. Dragomir, Yang Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 252
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling
Junjie Xu, Zhe Wan, Minyue Tang, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 229
Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
Mohamed Bouattour, Éric Raymond, Shukui Qin, et al.
Hepatology (2017) Vol. 67, Iss. 3, pp. 1132-1149
Open Access | Times Cited: 226
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma
Ning Lyu, Yanan Kong, Luwen Mu, et al.
Journal of Hepatology (2018) Vol. 69, Iss. 1, pp. 60-69
Closed Access | Times Cited: 215
Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
Shuzhen Chen, Qiqi Cao, Wen Wen, et al.
Cancer Letters (2019) Vol. 460, pp. 1-9
Closed Access | Times Cited: 209
Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
Giovanni Luca Beretta, Giuliana Cassinelli, Marzia Pennati, et al.
European Journal of Medicinal Chemistry (2017) Vol. 142, pp. 271-289
Closed Access | Times Cited: 189
Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma
Aparna Jayachandran, Bijay Dhungel, Jason C. Steel
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 179
Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis
Jiao Feng, Weiqi Dai, Yuqing Mao, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 167
Recent advances in systemic therapy for hepatocellular carcinoma
Huajun Zhang, Wuyang Zhang, Longying Jiang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 162
Immune Checkpoint Inhibitors in the Treatment of HCC
Clelia Donisi, Marco Puzzoni, Pina Ziranu, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 108
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer
Hao Shen, Boqiang Liu, Junjie Xu, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 104
SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase
Feng-li Xu, Xiaohong Wu, Chang Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 47
Mechanism of sorafenib resistance associated with ferroptosis in HCC
Lingling Guo, Cuntao Hu, Mengwen Yao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 44
A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer
Wenbo Yao, Qian Ba, Xiaoguang Li, et al.
EBioMedicine (2017) Vol. 22, pp. 58-67
Open Access | Times Cited: 138
Melatonin‐induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy
Néstor Prieto‐Domínguez, Raquel Ordóñez, Ana María Cameán Fernández, et al.
Journal of Pineal Research (2016) Vol. 61, Iss. 3, pp. 396-407
Open Access | Times Cited: 126
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 47, pp. 100646-100646
Closed Access | Times Cited: 112
The Epigenetic Regulation of HCC Metastasis
Tae‐Su Han, Hyun Seung Ban, Keun Hur, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 12, pp. 3978-3978
Open Access | Times Cited: 105
Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells
Jiejie Dong, Bo Zhai, Weihua Sun, et al.
PLoS ONE (2017) Vol. 12, Iss. 9, pp. e0185088-e0185088
Open Access | Times Cited: 102
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma
Mengxi Huang, Cheng Chen, Jian Geng, et al.
Cancer Letters (2017) Vol. 398, pp. 12-21
Closed Access | Times Cited: 98
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma
Sainan Li, Weiqi Dai, Wenhui Mo, et al.
International Journal of Cancer (2017) Vol. 141, Iss. 12, pp. 2571-2584
Open Access | Times Cited: 98
Page 1 - Next Page

Scroll to top